跳至主要内容
临床试验/NL-OMON53064
NL-OMON53064招募中不适用

Zimmer Maxera acetabular system in total hip arthroplasty: a multi-center, prospective, non-controlled post marktet clinical follow-up study - Maxera study

Zimmer Biomet GmbH0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patient is 18 to 75 years of age, inclusive.
  • Patient is skeletally mature.
  • Patient qualifies for primary unilateral or simultaneous bilateral total hip
  • arthroplasty
  • (THA) based on physical exam and medical history including at least one of the
  • o Osteoarthritis
  • o Avascular necrosis (AVN)
  • o Inflammatory arthritis
  • o Rheumatoid arthritis with adequate bone quality
  • o Post-traumatic arthritis
  • o Congenital hip dysplasia.
  • Patient has no history of previous total hip replacement or arthrodesis of
  • the affected hip
  • Patient has a Harris Hip Score <70 in the affected hip and a Harris Hip pain
  • moderate, marked, or disabled.
  • Patient is willing and able to provide written informed consent.
  • Patient is willing and able to cooperate in the required post-operative
  • Patient is willing and able to complete scheduled follow-up evaluations as
  • described in
  • the Informed Consent.

排除标准

  • The patient is:
  • o A prisoner
  • o Mentally incompetent or unable to understand what participation in the study
  • o A known alcohol or drug abuser
  • o Anticipated to be non-compliant
  • The patient has a neuromuscular disorder, vascular disorder or other
  • condition that
  • could contribute to prosthesis instability, prosthesis fixation failure, or
  • complications in
  • postoperative care.
  • The patient has local bone tumors and/or cysts in the portion of bone to be
  • retained in
  • the operative hip that could inhibit implant fixation.
  • The patient has insufficient bone stock or poor bone quality to fix the
  • component. Insufficient
  • bone stock exists in the presence of metabolic bone disease (i.e. osteoporosis),
  • cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be
  • to assess the presence of adequate bone stock.
  • The patient has rapid disease progression as obvious by joint destruction or
  • bone absorption
  • seen on x-ray.
  • The patient has osteoradionecrosis in the affected hip.
  • The patient has a neuromuscular condition in the ipsilateral or contralateral
  • affects lower limb function.
  • The patient has loss of abductor musculature in the affected hip.
  • The patient has a vascular (large and small vessel disease) insufficiency.
  • The patient has had previous prosthetic hip replacement device (any type,
  • surface replacement arthroplasty, endoprosthesis, etc.) in the joint to be
  • The patient has had previous girdlestone procedure (resection arthroplasty)
  • or surgical
  • fusion of the hip to be operated.
  • Emilie Rohmer, 11.05.2012, Rev. 0 page 17 of 57
  • F WT.30.0108-1 Effective Date 21. Okt. 2010
  • Clinical Investigation Plan Revision 0
  • The patient has an acute femoral neck fracture in the operative hip.
  • The patient has had a procedure on the operative hip in the last 6 months
  • (i.e. arthroscopy,
  • ORIF femoral neck fracture, etc).
  • The patient has undergone a total hip replacement, endoprosthesis, or surface
  • arthroplasty
  • of the contralateral (opposite side) hip within the past 6 months regardless of
  • whether the previous hip was enrolled in this clinical study.
  • The patient has a moderate to severe limb length discrepancy greater than 3.2
  • The patient has an active, old or remote infection in or about the affected
  • hip joint or an
  • infection distant from the hip joint that may spread to the hip hematogenously.
  • The patient has poor skin coverage around the affected hip joint.
  • The patient has a diagnosed systemic disease that could affect his/her safety
  • study outcome.
  • The patient is currently receiving, or within the past three months, has
  • 另有 15 项未显示

研究者

发起方
Zimmer Biomet GmbH

相似试验